Javier
Rodríguez Rodríguez
Consultor Médico
![Foto de Javier](/img/nophoto.png)
![Foto de Clínica Universitaria de Navarra](/img/noimage_org.png)
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (39)
2024
-
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
British Journal of Surgery, Vol. 111, Núm. 3
2023
-
"What medical students with better academic results do: a cross-sectional analysis"
BMC medical education, Vol. 23, Núm. 1, pp. 19
2022
-
Long-Term Outcome of Critically Ill Advanced Cancer Patients Managed in an Intermediate Care Unit
Journal of Clinical Medicine, Vol. 11, Núm. 12, pp. 3472
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
-
Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse
Cancers, Vol. 11, Núm. 5
2017
-
Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases
Future Oncology, Vol. 13, Núm. 23, pp. 2065-2082
2016
-
SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer
Journal of Clinical Oncology, Vol. 34, Núm. 15, pp. 1723-1731
2014
-
Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer
Journal of Gastrointestinal Oncology, Vol. 5, Núm. 2, pp. 148-153
2013
-
KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
Oncology Letters, Vol. 6, Núm. 5, pp. 1343-1345
-
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy
Diseases of the Colon and Rectum, Vol. 56, Núm. 4, pp. 416-421
2012
-
Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
European Journal of Cancer, Vol. 48, Núm. 12, pp. 1774-1780
-
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial
International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593
-
Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array
World Journal of Gastroenterology, Vol. 18, Núm. 7, pp. 637-645
-
Identification of predictive circulating biomarkers of bevacizumab- containing regimen efficacy in pre-treated metastatic colorectal cancer patients
British Journal of Cancer, Vol. 107, Núm. 2, pp. 287-290
2011
-
Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy
European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847
-
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142
-
Transthoracic oesophagectomy with lymphadenectomy in 100 oesophageal cancer patients. Multidisciplinary approach
Clinical and Translational Oncology, Vol. 13, Núm. 12, pp. 899-903
2010
-
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535
-
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis
British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994